



2022 MX-B Intended Responses

ANTIBODY SPECIFICITIES by FLOW

MX-07P		MX-08P	
Class I Results	Class II Results	Class I Results	Class II Results
B62, B77, B76, B75, B63, B57, B13, B46, B72, B50, B71, B49, B56, B35, B53, B52, B58, B51, B78	DR13, DR11, DR17, DR14, DR18, DR12, DR8, DR52	B18, B78, B51, B64, B65, B67, B52, B39, B81, B8, B61, B55, B54, B60, B56, B48, B42, B63, A33, C15, B41, B13, B59, B57, B7, B82, B71, B38, B35, B75, B53, B37, B77, A69	Negative
MX-09P		MX-10P	
Class I Results	Class II Results	Class I Results	Class II Results
A1, B76, A80, A36, A23, B45, B27, A24, A43, B44, A29, B73, B7, B60, A26, B61, B82, B81, C9, B46, C10, C8, C1, B13, C14, B48, C12, C16, B67, C7, B47, B42, B56, B8, B55, B54, B41, A11, B50, B39, B18, B72, B62, B64, B35, B78, B75, A66, B71, B65, A25, A3	DR13, DR11, DR8, DR17, DR14, DR12, DR52, DR18, DR16, DRB5*01, DR103, DR7, DR15, DQ7, DR4, DQB1*06	Negative	Negative

CDC- complement-dependent cytotoxicity antibody specificities are no longer a reportable method due to inadequate group size.

CROSSMATCH RESULTS

MX-07P (1 st Set)		
Method	Against MX-11C	Against MX-12C
Direct Cytotoxicity	T and B - both NEGATIVE	T and B - both NEGATIVE
Flow	T and B - both NEGATIVE	T and B - both NEGATIVE
MX-08P (2 nd Set)		
Method	Against MX-11C	Against MX-12C
Direct Cytotoxicity	T and B - both NEGATIVE	T and B - both NEGATIVE
Flow	T and B - both POSITIVE	T and B - both POSITIVE
MX-09P (3 rd Set)		
Method	Against MX-11C	Against MX-12C
Direct Cytotoxicity	T and B - both NEGATIVE	T and B - both POSITIVE
Flow	T and B - both POSITIVE	T and B - both POSITIVE
MX-10P (4 th Set)		
Method	Against MX-11C	Against MX-12C
Direct Cytotoxicity	T and B - both NEGATIVE	T and B - both NEGATIVE
Flow	T and B - both NEGATIVE	T and B - both NEGATIVE